<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16042786</article-id><article-id pub-id-type="pmc">1183196</article-id><article-id pub-id-type="publisher-id">1471-2407-5-87</article-id><article-id pub-id-type="doi">10.1186/1471-2407-5-87</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Park</surname><given-names>Se Hoon</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hematoma@gilhospital.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Bang</surname><given-names>Soo-Mee</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>smbang@gilhospital.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Cho</surname><given-names>Eun Kyung</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ekcho@gilhospital.com</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Shin</surname><given-names>Dong Bok</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dbs@gilhospital.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Lee</surname><given-names>Jae Hoon</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jhlee@gilhospital.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Lee</surname><given-names>Woon KI</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>lwk@gilhospital.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Chung</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mc@gilhospital.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Hematology and Oncology, Department of Internal Medicine, Gachon Medical School Gil Medical Center, Incheon 405-760, Korea</aff><aff id="I2"><label>2</label>Department of General Surgery, Gachon Medical School Gil Medical Center, Incheon 405-760, Korea</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>22</day><month>7</month><year>2005</year></pub-date><volume>5</volume><fpage>87</fpage><lpage>87</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/5/87"/><history><date date-type="received"><day>31</day><month>1</month><year>2005</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2005</year></date></history><copyright-statement>Copyright &#x000a9; 2005 Park et al; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Background</title><p>Published data suggests that docetaxel combined with 5-fluorouracil (5-FU) may have synergistic activity in treating advanced gastric cancer. We performed a phase I study of docetaxel and 5-FU to determine the maximum tolerated dose (MTD), the recommended dose for phase II studies, and the safety of this combination.</p></sec><sec sec-type="methods"><title>Methods</title><p>Eligible patients had recurrent and/or metastatic advanced gastric cancer with normal cardiac, renal and hepatic function. Traditional phase I methodology was employed in assessing dose-limiting toxicity (DLT) and MTD. On day 1 every 3 weeks, docetaxel 75 mg/m<sup>2 </sup>(fixed dose) was infused over 1-h, followed immediately by 5-FU as a 5-day continuous infusion.</p></sec><sec><title>Results</title><p>Dose escalation schema was as follows: dose level (DL) 1 (5-FU 250 mg/m<sup>2</sup>/day), 2 (500), 3 (750), and 4 (1000). Three patients were enrolled on DL1, without DLT. On DL2, 1 DLT (grade 3 stomatitis) was developed in first 3 patients, and this cohort was expanded to 6 patients. Three patients had been enrolled on DL3. Because two out of 3 patients had DLTs, the MTD was reached at DL3.</p></sec><sec><title>Conclusion</title><p>The recommended phase II dose of this combination is 75 mg/m<sup>2 </sup>docetaxel on day 1 immediately followed by a 5-day continuous infusion of 5-FU 500 mg/m<sup>2</sup>/day.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Gastric cancer remains the most common cause of cancer-related death in Korea [<xref ref-type="bibr" rid="B1">1</xref>]. For patients with unresectable, locally advanced, or metastatic disease, chemotherapy can provide significant palliation of symptoms [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. When used as single agents, 5-fluorouracil (5-FU), doxorubicin, cisplatin, and mitomycin C are considered active in gastric cancer, producing response rates in up to 20% of patients [<xref ref-type="bibr" rid="B4">4</xref>]. Of these, 5-FU is an central cytostatic antimetabolite with a broad range of antitumor activity in breast, gastrointestinal, head and neck, and ovarian cancers. When given as a prolonged continuous infusion, stomatitis and diarrhea are the principal toxicities, whereas myelosuppression is more commonly observed with intravenous bolus injections [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Because 5-FU has demonstrated synergistic interaction with many antineoplastic agents, it is currently most often administered in the setting of combination chemotherapy regimens. However, most trials with different combinations of these drugs provided similar survivals ranging from 6 to 10 months [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. No regimen has been universally recognized as standard.</p><p>Among the new agents, docetaxel is a novel semisynthetic taxane with significant antitumor activity and manageable toxicity consisting primarily of myelosuppression [<xref ref-type="bibr" rid="B9">9</xref>]. Results of docetaxel-containing regimen in the treatment of gastric cancer are encouraging. Phase I and II clinical trials have confirmed that docetaxel is effective in patients with advanced gastric cancer when used as monotherapy, yielding response rates of 20% [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Docetaxel and 5-FU are highly synergistic [<xref ref-type="bibr" rid="B12">12</xref>], and clinical evidence suggests lack of cross-resistance.</p><p>When this study was initiated, most previous studies used docetaxel 60&#x02013;85 mg/m<sup>2 </sup>on day 1, followed by a 5-day continuous infusion of 5-FU 500&#x02013;1000 mg/m<sup>2</sup>/day, every 3 weeks [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. However, we had experienced severe toxicities such as febrile neutropenia and grade 3 or 4 stomatitis in treating patients with advanced gastric cancer as a practice with docetaxel 75 mg/m<sup>2 </sup>and 5-FU 1000 mg/m<sup>2</sup>/day for 5 days. Therefore, we performed a phase I study of docetaxel and 5-FU to determine the maximum tolerated dose (MTD) and the safety of this combination.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>This was a phase I dose-escalating study conducted between Mar 2002 and Aug 2002. The study was conducted according to the principles stated in the latest version of the Declaration of Helsinki. This study protocol was reviewed and approved by the Gil Medical Center institutional review board, and signed informed consent was obtained from all patients prior to their enrollment.</p><p>Patients enrolled into this study had to be at least 18 years of age and have a histologically confirmed diagnosis of metastatic or recurrent gastric adenocarcinoma that was previously treated with, though not necessarily resistant to, cytotoxic chemotherapy. The patients were required to have a Eastern Cooperative Oncology Group (ECOG) performance status &#x02264;2, normal blood counts, normal renal and hepatic functions, no history of anaphylaxis and no peripheral neuropathy of any origin. Patients had to have received at least one chemotherapy regimen, either as adjuvant treatment or for metastatic disease. Patients could have received prior 5-FU, provided it was administered in intravenous bolus or in oral form, but not with paclitaxel or docetaxel. Patients had to have fully recovered from the toxic effects of previous chemotherapy except for alopecia.</p></sec><sec><title>Treatment plan</title><p>The treatment consisted of docetaxel 75 mg/m<sup>2 </sup>on day 1 in a 1-h infusion followed by 5-FU in continuous infusion from day 1 to day 5, according to the escalating dose levels. The starting dose of 5-FU was 250 mg/m<sup>2</sup>/day for 5 days. In the absence of DLT, dose escalation in additional cohorts continued at a dose increase of 250 mg/m<sup>2</sup>/dose. Traditional phase I methodology was employed in assessing dose-limiting toxicity (DLT) and MTD. Patients were to be treated at the same dose level in groups of three. If no DLT, defined as febrile neutropenia and/or grade 3/4 toxicity of any other kind apart from alopecia, occurred, the next 3 patients were treated at the next higher dose level. If one DLT occurred, 3 additional patients had to be treated at the same dose level. If 2 or more DLTs occurred at a given dose level, the MTD would be considered to be reached and the dose escalation had to be stopped. The dose just below would be considered to be the recommended dose for further evaluation in phase II trials.</p><p>Only the first cycle of treatment was evaluated to determine DLT. However, to adequately determine to safety of this combination, the recruitment of further patients at the recommended dose level was planned in a subsequent phase II study [<xref ref-type="bibr" rid="B16">16</xref>]. All patients received a standard supportive regimen consisting of dexamethasone and 5-HT3 inhibitors. The use of hematological growth factors was not allowed during the first cycle of treatment, but was permitted thereafter among patients who had one episode of febrile neutropenia or infection according to the guideline provided by American Society of Clinical Oncology [<xref ref-type="bibr" rid="B17">17</xref>].</p></sec><sec><title>Patient evaluation</title><p>Toxicity was graded according to National Cancer Institute Common Toxicity Criteria for adverse events (NCI-CTC) [<xref ref-type="bibr" rid="B18">18</xref>]. Dose modifications were planned for toxicity. The primary objective of the study was to define the MTD of the regimen under investigation. Evaluation at baseline and during the study included a medical history, data on toxicity and physical examination every courses.</p></sec></sec><sec><title>Results</title><sec><title>Patient characteristics</title><p>Sixteen patients received a total of 45 cycles of treatment (median 3, range 1&#x02013;6). Patient characteristics are listed in Table <xref ref-type="table" rid="T1">1</xref>. All patients previously received one cytotoxic chemotherapy regimen, with 88% having received prior fluoropyrimidines. Previous chemotherapy was commonly administered as adjuvant treatment (4 patients, 25%) or for metastatic disease (12 patients; 75%). Twelve patients (75%) had no measurable lesions to evaluate treatment efficacy.</p></sec><sec><title>Toxicity</title><p>All patients were evaluable for toxicity. Of three patients enrolled on dose level 1 (5-FU 250 mg/m<sup>2</sup>/day for 5 days), none experienced DLT. On dose level 2 (5-FU 500 mg/m<sup>2</sup>/day for 5 days), a 63-year-old male with peritoneal dissemination developed grade 3 stomatitis and fatigue. Three additional patients were enrolled at this dose level did not experience DLT. Dose escalation thus proceeded to dose level 3 (5-FU 750 mg/m<sup>2</sup>/day for 5 days). One of the 3 initial patients at this level, a 57-year-old male with peritoneal dissemination developed grade 3 stomatitis and another patient, a 60-year-old male with liver metastasis had febrile neutropenia. Because two out of 3 patients had DLTs, the MTD was reached at dose level 3. Dose level 2 was therefore the recommended regimen with docetaxel 75 mg/m<sup>2 </sup>on day 1 and 5-FU 750 mg/m<sup>2</sup>/day in a 5-day continuous infusion.</p><p>Toxicity analysis is based on 16 patients and 45 cycles of treatment. Table <xref ref-type="table" rid="T2">2</xref> summarizes DLTs per patients and per cycles. No treatment-related death was observed.</p></sec></sec><sec><title>Discussion</title><p>This phase I trial determined the recommended phase II dose of 5-FU to be 500 mg/m<sup>2</sup>/day as a 5-day continuous infusion when combined with 75 mg/m<sup>2 </sup>docetaxel every 3 weeks. DLTs included stomatitis, neutropenia, diarrhea, and asthenia. Toxicity in our study did not differ significantly from that seen in other phase I studies that evaluated docetaxel combined with 5-FU continuous infusion. A phase I trial showed that docetaxel at 85 mg/m<sup>2 </sup>with 5-FU given in continuous infusion over 5 days at 750 mg/m<sup>2</sup>/day was tolerable without any major mucosal toxicity or any substantial increase in docetaxel-induced myelotoxicity [<xref ref-type="bibr" rid="B12">12</xref>]. Ando <italic>et al</italic>. [<xref ref-type="bibr" rid="B13">13</xref>] determined the MTDs of docetaxel and 5-FU on this schedule to be 50 mg/m<sup>2 </sup>and 500 mg/m<sup>2</sup>/day, respectively, and neutropenia to be the primary DLT, with diarrhea also dose limiting. Using a similar schedule, Van den Neste <italic>et al</italic>. [<xref ref-type="bibr" rid="B14">14</xref>] reported the MTDs of docetaxel and 5-FU to be 85 mg/m<sup>2 </sup>and 750 mg/m<sup>2</sup>/day, with diarrhea, stomatitis and neutropenia as DLTs.</p><p>Because of the relatively high incidence of hematologic toxicity induced by docetaxel, it was felt that only a moderately myelotoxic agent could be added as a combination. 5-FU given in continuous infusion could be an interesting option since it is known to induce very little myelotoxicity, if any.</p><p>With the addition of 5-FU, the main changes in the non-hematologic toxicity were observed in the occurrence of stomatitis and diarrhea, and in the appearance of hand-foot syndrome. All three toxicities are known to be associated with 5-FU. Hawkins <italic>et al</italic>. [<xref ref-type="bibr" rid="B15">15</xref>] compared docetaxel with the addition of irinotecan or 5-FU in a randomized phase II study. Both docetaxel/irinotecan and docetaxel/5-FU were well-tolerated with acceptable toxicity profiles. Three-drug combination of docetaxel, 5-FU and cisplatin for patients with gastric cancer was also investigated by some authors. Roth <italic>et al</italic>. [<xref ref-type="bibr" rid="B19">19</xref>] administered combination chemotherapy with docetaxel 85 mg/m<sup>2</sup>, cisplatin 75 mg/m<sup>2</sup>, and 5-FU 300 mg/m<sup>2</sup>/day on days 1&#x02013;14, resulting in a 51% objective response. The major toxicity was neutropenia which reached grade 3 or 4 in 79% of 52 patients. Ajani <italic>et al</italic>. [<xref ref-type="bibr" rid="B20">20</xref>] evaluated a combination of docetaxel, cisplatin, and 5-FU (DCF) for chemotherapy-na&#x000ef;ve patients with advanced gastric cancer. They achieved a response rate of 39% and median survival of 10.2 months, and toxicity was manageable. It is apparent that the more complex a chemotherapy regimen, the more toxic and difficult for patients to tolerate. Although cisplatin is often used in combination with other agents, it is well known that cisplatin is associated with significant toxicity and usually requires high level of clinical monitoring and supportive care including intensive intravenous hydration. Thuss-Patience <italic>et al</italic>. [<xref ref-type="bibr" rid="B21">21</xref>] recently reported that docetaxel/5-FU had similar efficacy to epirubicin/cisplatin/5-FU (ECF) and even to DCF.</p><p>Since nearly 80% of the patients did not have measurable disease, an efficacy assessment could not be performed in this patient population. Our randomized phase II trial with docetaxel/5-FU versus paclitaxel/5-FU is currently ongoing [<xref ref-type="bibr" rid="B16">16</xref>].</p></sec><sec><title>Conclusion</title><p>In conclusion, the recommended dose of this combination is 75 mg/m<sup>2 </sup>docetaxel on day 1 immediately followed by a 5-day continuous infusion of 5-FU 500 mg/m<sup>2</sup>/day. Further evaluation of efficacy and safety is currently underway in a randomized phase II trial of 5-FU combined with docetaxel versus paclitaxel.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SHP collected the data, performed the statistical analysis and drafted the manuscript. SB, EKC, JHL, WKL and MC followed the patients. DBS designed the study and helped with the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/5/87/prepub"/></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>JM</given-names></name><name><surname>Won</surname><given-names>YJ</given-names></name><name><surname>Jung</surname><given-names>KW</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name></person-group><article-title>Annual report of the Korean central cancer registry program 2000</article-title><source>Cancer Res Treat</source><year>2002</year><volume>34</volume><fpage>77</fpage><lpage>83</lpage></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pyrhonen</surname><given-names>S</given-names></name><name><surname>Kuitunen</surname><given-names>T</given-names></name><name><surname>Nyandoto</surname><given-names>P</given-names></name><name><surname>Kouri</surname><given-names>M</given-names></name></person-group><article-title>Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer</article-title><source>Br J Cancer</source><year>1995</year><volume>71</volume><fpage>587</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">7533517</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Ekstrom</surname><given-names>K</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Sjoden</surname><given-names>PO</given-names></name><name><surname>Haglund</surname><given-names>U</given-names></name><name><surname>Svensson</surname><given-names>C</given-names></name><name><surname>Enander</surname><given-names>LK</given-names></name><name><surname>Linne</surname><given-names>T</given-names></name><name><surname>Sellstrom</surname><given-names>H</given-names></name><name><surname>Heuman</surname><given-names>R</given-names></name></person-group><article-title>Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer</article-title><source>Ann Oncol</source><year>1997</year><volume>8</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">9093725</pub-id><pub-id pub-id-type="doi">10.1023/A:1008243606668</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murad</surname><given-names>AM</given-names></name></person-group><article-title>Chemotherapy for Advanced Gastric Cancer: Focus on New Agents and Combinations</article-title><source>Cancer Control</source><year>1999</year><volume>6</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">10758568</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>P</given-names></name><name><surname>Baker</surname><given-names>LH</given-names></name><name><surname>Reed</surname><given-names>ML</given-names></name><name><surname>Vaitkevicius</surname><given-names>VK</given-names></name></person-group><article-title>Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma</article-title><source>Cancer</source><year>1975</year><volume>36</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">1203840</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lokich</surname><given-names>JJ</given-names></name><name><surname>Ahlgren</surname><given-names>JD</given-names></name><name><surname>Gullo</surname><given-names>JJ</given-names></name><name><surname>Philips</surname><given-names>JA</given-names></name><name><surname>Fryer</surname><given-names>JG</given-names></name></person-group><article-title>A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">2926468</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cullinan</surname><given-names>SA</given-names></name><name><surname>Moertel</surname><given-names>CG</given-names></name><name><surname>Wieand</surname><given-names>HS</given-names></name><name><surname>O'Connell</surname><given-names>MJ</given-names></name><name><surname>Poon</surname><given-names>MA</given-names></name><name><surname>Krook</surname><given-names>JE</given-names></name><name><surname>Mailliard</surname><given-names>JA</given-names></name><name><surname>Tschetter</surname><given-names>LK</given-names></name></person-group><article-title>Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><fpage>412</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">8113849</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Shirao</surname><given-names>K</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Hyodo</surname><given-names>I</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Yamamichi</surname><given-names>N</given-names></name><name><surname>Miyata</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name></person-group><article-title>Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>54</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">12506170</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2003.04.130</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ringel</surname><given-names>I</given-names></name><name><surname>Horwitz</surname><given-names>SB</given-names></name></person-group><article-title>Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol</article-title><source>J Natl Cancer Inst</source><year>1991</year><volume>83</volume><fpage>288</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">1671606</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sulkes</surname><given-names>A</given-names></name><name><surname>Smyth</surname><given-names>J</given-names></name><name><surname>Sessa</surname><given-names>C</given-names></name><name><surname>Dirix</surname><given-names>LY</given-names></name><name><surname>Vermorken</surname><given-names>JB</given-names></name><name><surname>Kaye</surname><given-names>S</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Franklin</surname><given-names>H</given-names></name><name><surname>LeBail</surname><given-names>N</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name></person-group><article-title>Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group</article-title><source>Br J Cancer</source><year>1994</year><volume>70</volume><fpage>380</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">7914428</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Einzig</surname><given-names>AI</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Remick</surname><given-names>SC</given-names></name><name><surname>Karp</surname><given-names>DD</given-names></name><name><surname>O'Dwyer</surname><given-names>PJ</given-names></name><name><surname>Stewart</surname><given-names>JA</given-names></name><name><surname>Benson</surname><given-names>AB</given-names></name></person-group><article-title>Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293</article-title><source>Med Oncol</source><year>1996</year><volume>13</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">9013471</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>HA</given-names><suffix>3rd</suffix></name></person-group><article-title>Docetaxel in combination with fluorouracil for advanced solid tumors</article-title><source>Oncology (Williston Park)</source><year>1997</year><volume>11</volume><fpage>50</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9364544</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Ying</surname><given-names>DF</given-names></name><name><surname>Omuro</surname><given-names>Y</given-names></name><name><surname>Katsumata</surname><given-names>N</given-names></name><name><surname>Narabayashi</surname><given-names>M</given-names></name><name><surname>Tokue</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Igarashi</surname><given-names>T</given-names></name><name><surname>Wakita</surname><given-names>H</given-names></name><name><surname>Ohtsu</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>I</given-names></name><name><surname>Taguchi</surname><given-names>T</given-names></name></person-group><article-title>A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>1937</fpage><lpage>1943</lpage><pub-id pub-id-type="pmid">9667671</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Den Neste</surname><given-names>E</given-names></name><name><surname>de Valeriola</surname><given-names>D</given-names></name><name><surname>Kerger</surname><given-names>J</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Kusenda</surname><given-names>Z</given-names></name><name><surname>Brassinne</surname><given-names>C</given-names></name><name><surname>Bartholomeus</surname><given-names>S</given-names></name><name><surname>Selleslags</surname><given-names>J</given-names></name><name><surname>Hennebert</surname><given-names>P</given-names></name><name><surname>Wythouck</surname><given-names>H</given-names></name><name><surname>Cazenave</surname><given-names>I</given-names></name><name><surname>Lefresne-Soulas</surname><given-names>F</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name></person-group><article-title>A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10656433</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>R</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Soerbye</surname><given-names>H</given-names></name><name><surname>Adenis</surname><given-names>A</given-names></name><name><surname>Canon</surname><given-names>JL</given-names></name><name><surname>Lopez-Vivanco</surname><given-names>G</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Stenger</surname><given-names>P</given-names></name><name><surname>Zuber</surname><given-names>E</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name></person-group><article-title>Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC)</article-title><source>Proc Am Soc Clin Oncol</source><year>2003</year><volume>22</volume><fpage>257 (abstr 1032)</fpage></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>WK</given-names></name><name><surname>Bang</surname><given-names>SM</given-names></name><name><surname>Cho</surname><given-names>EK</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>Interim analysis from a prospective randomized trial of taxanes plus 5-FU in advanced gastric cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>2004</year><volume>22</volume><fpage>361 (abstr 4191)</fpage></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozer</surname><given-names>H</given-names></name><name><surname>Armitage</surname><given-names>JO</given-names></name><name><surname>Bennett</surname><given-names>CL</given-names></name><name><surname>Crawford</surname><given-names>J</given-names></name><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>Pizzo</surname><given-names>PA</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>TJ</given-names></name><name><surname>Somlo</surname><given-names>G</given-names></name><name><surname>Wade</surname><given-names>JC</given-names></name><name><surname>Wade</surname><given-names>JL</given-names></name><name><surname>Winn</surname><given-names>RJ</given-names></name><name><surname>Wozniak</surname><given-names>AJ</given-names></name><name><surname>Somerfield</surname><given-names>MR</given-names></name></person-group><article-title>2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>3558</fpage><lpage>3585</lpage><pub-id pub-id-type="pmid">11032599</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Welch</surname><given-names>SR</given-names></name><name><surname>Raber</surname><given-names>MN</given-names></name><name><surname>Fields</surname><given-names>WS</given-names></name><name><surname>Krakoff</surname><given-names>IH</given-names></name></person-group><article-title>Comprehensive criteria for assessing therapy-induced toxicity</article-title><source>Cancer Invest</source><year>1990</year><volume>8</volume><fpage>147</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">2400936</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Maibach</surname><given-names>R</given-names></name><name><surname>Fazio</surname><given-names>N</given-names></name><name><surname>Sessa</surname><given-names>C</given-names></name><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Morant</surname><given-names>R</given-names></name><name><surname>Herrmann</surname><given-names>R</given-names></name><name><surname>Borner</surname><given-names>MM</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name></person-group><article-title>5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial</article-title><source>Ann Oncol</source><year>2004</year><volume>15</volume><fpage>759</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">15111343</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdh187</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Moiseyenko</surname><given-names>V</given-names></name><name><surname>Tjulandin</surname><given-names>S</given-names></name><name><surname>Fodor</surname><given-names>M</given-names></name><name><surname>Majlis</surname><given-names>A</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Zuber</surname><given-names>E</given-names></name><name><surname>Blattmann</surname><given-names>A</given-names></name></person-group><article-title>Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325)</article-title><source>Proc Am Soc Clin Oncol</source><year>2003</year><volume>22</volume><fpage>249 (abstr 999)</fpage></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thuss-Patience</surname><given-names>PC</given-names></name><name><surname>Kretzschmar</surname><given-names>A</given-names></name><name><surname>Repp</surname><given-names>M</given-names></name><name><surname>Kingreen</surname><given-names>D</given-names></name><name><surname>Hennesser</surname><given-names>D</given-names></name><name><surname>Micheel</surname><given-names>S</given-names></name><name><surname>Pink</surname><given-names>D</given-names></name><name><surname>Scholz</surname><given-names>C</given-names></name><name><surname>Dorken</surname><given-names>B</given-names></name><name><surname>Reichardt</surname><given-names>P</given-names></name></person-group><article-title>Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>494</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">15659494</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.02.163</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Number of patients</td><td align="left">N = 16</td><td></td></tr></thead><tbody><tr><td align="left">Age</td><td></td><td></td></tr><tr><td align="left">&#x02003;Median</td><td align="left">59</td><td></td></tr><tr><td align="left">&#x02003;Range</td><td align="left">36&#x02013;73</td><td></td></tr><tr><td align="left">Male:female</td><td align="left">14:2</td><td></td></tr><tr><td align="left">ECOG performance status</td><td></td><td></td></tr><tr><td align="left">&#x02003;0</td><td align="left">6</td><td align="left">37%</td></tr><tr><td align="left">&#x02003;1</td><td align="left">8</td><td align="left">50%</td></tr><tr><td align="left">&#x02003;2</td><td align="left">2</td><td align="left">13%</td></tr><tr><td align="left">Disease status</td><td></td><td></td></tr><tr><td align="left">&#x02003;Primary metastatic</td><td align="left">12</td><td align="left">75%</td></tr><tr><td align="left">&#x02003;Locally-advanced</td><td align="left">4</td><td align="left">25%</td></tr><tr><td align="left">Prior chemotherapy</td><td></td><td></td></tr><tr><td align="left">&#x02003;Uracil-tegafur</td><td align="left">4</td><td align="left">25%</td></tr><tr><td align="left">&#x02003;5-FU bolus + folinic acid</td><td align="left">1</td><td align="left">6%</td></tr><tr><td align="left">&#x02003;5-FU + cisplatin</td><td align="left">4</td><td align="left">25%</td></tr><tr><td align="left">&#x02003;Epirubicin + cisplatin + capecitabine</td><td align="left">5</td><td align="left">31%</td></tr><tr><td align="left">&#x02003;Epirubicin + doxorubicin + cisplatin</td><td align="left">2</td><td align="left">13%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Dose-limiting toxicities (DLTs) according to dose level.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Dose level (5-FU/day)</td><td align="center">Pts/cycles</td><td align="center">After first cycle</td><td align="center" colspan="5">After all courses (pts/cycles)</td></tr><tr><td></td><td></td><td></td><td colspan="5"><hr></hr></td></tr><tr><td></td><td></td><td></td><td align="center">Neutropenia</td><td align="center">FN<sup>1</sup></td><td align="center">stomatitis</td><td align="center">diarrhea</td><td align="center">asthenia</td></tr></thead><tbody><tr><td align="left">Level 1 (250 mg)</td><td align="center">3/4</td><td align="center">None</td><td></td><td></td><td align="center">1/1</td><td></td><td align="center">1/1</td></tr><tr><td align="left">Level 2 (500 mg)</td><td align="center">10/35</td><td align="center">Stomatitis (1)</td><td align="center">4/5</td><td></td><td align="center">6/11</td><td align="center">1/1</td><td align="center">4/7</td></tr><tr><td align="left">Level 3 (750 mg)</td><td align="center">3/4</td><td align="center">Stomatitis (1)<break/>FN (1)</td><td align="center">2/2</td><td align="center">1/1</td><td align="center">2/2</td><td align="center">1/1</td><td align="center">1/1</td></tr></tbody></table><table-wrap-foot><p>1 FN denotes febrile neutropenia.</p></table-wrap-foot></table-wrap></sec></back></article>


